Glimepiride Sandoz Ltd (Glimepiride)

Glimepiride Sandoz Ltd is indicated for the management of elevated blood glucose in patients with type 2 diabetes mellitus, typically when diet, exercise, and other oral agents are insufficient.

• Improves glycemic control as monotherapy in adults with type 2 diabetes.
• Can be combined with metformin or other oral antidiabetics to enhance glucose lowering.
• May be used as part of a step‑wise treatment algorithm after lifestyle measures have failed.
• Helps reduce HbA1c levels when taken consistently with meals.
• May be prescribed for patients with renal impairment after dose adjustment considerations.
• Can be part of combination therapy with a DPP‑4 inhibitor for additional post‑prandial glucose control.

The safety profile of glimepiride includes a range of adverse effects that vary in frequency and severity.

Common

• Mild hypoglycemia, often occurring if a meal is missed or delayed.
• Nausea, abdominal discomfort, or dyspepsia.
• Headache, dizziness, or light‑headed feeling.
• Weight gain related to increased insulin secretion.
• Transient visual disturbances or blurred vision.

Serious

• Severe hypoglycemia that may cause loss of consciousness, seizures, or require emergency assistance.
• Allergic reactions such as rash, pruritus, swelling of the face, lips, or tongue.
• Rare cases of hepatic dysfunction or blood dyscrasias (e.g., neutropenia, thrombocytopenia).

When prescribing glimepiride, clinicians should consider several precautionary measures to ensure safe and effective use.

• Assess renal and hepatic function before initiating therapy and adjust dose if impairment is present.
• Monitor blood glucose regularly to detect hypoglycemia, especially during dose titration.
• Use caution in elderly patients who may be more susceptible to low blood sugar.
• Avoid use in patients with known sulfonylurea hypersensitivity.
• Review concomitant medications that may potentiate hypoglycemia.
• Counsel patients to take the medication with meals and not to skip meals.

Glimepiride may interact with other drugs, altering its effectiveness or increasing the risk of adverse events.

Avoid

• Concurrent use with other sulfonylureas or meglitinides, which can cause additive hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that may raise glimepiride plasma levels.
• High‑dose aspirin or NSAIDs that can potentiate hypoglycemic effects.
• Corticosteroids, which may increase blood glucose and counteract glimepiride's effect.

Use with caution

• Beta‑blockers, which may mask hypoglycemia symptoms.
• Thiazide diuretics, which can affect glucose metabolism.
• Antidepressants such as SSRIs, which have been reported to influence blood sugar control.
• ACE inhibitors, which may enhance insulin sensitivity and require glucose monitoring.
• Oral contraceptives, which may alter glimepiride metabolism and affect glycemic control.